EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry

M R Naber iD, A E van der Meulen, P W Voorneveld iD, S H C Veltkamp iD, A A van Bodegraven iD, A Bodelier, Z Mujagic iD, M Pierik iD, L M M Verleye iD, M Duijvestein iD, D G Bouwknegt iD, M C Visschedijk iD und 6 weitere

United European Gastroenterology Journal · 2026-02 · 14 (1)

DOI: 10.1002/ueg2.70141 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 05.12.2025. Verfasst von M R Naber und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Pyridines, Triazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Initiative on Crohn and Colitis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Filgotinib is a preferential Janus kinase 1 (JAK‐1) inhibitor registered for the treatment of ulcerative colitis (UC). Real‐world effectiveness of filgotinib, especially for difficult‐to‐treat (DTT, failure of ≥ 2 prior advanced therapies) patients, has been scarcely reported.

Objective

This study aimed to assess the effectiveness and safety of filgotinib for UC patients in routine care.

Methods

The Dutch ICC registry enrolled UC patients initiating filgotinib and prospectively evaluated outcomes up to 52 weeks. The primary outcome was corticosteroid‐free clinical remission (CSFR, Simple Clinical Colitis Activity Index [SCCAI] ≤ 2 without steroid use) at week 52. Secondary outcomes included clinical remission (SCCAI ≤ 2), biochemical remission (C‐reactive protein serum concentration < 5 mg/L and/or faecal calprotectin level < 250 μg/g), treatment persistence and safety.

Results

A total of 96 UC patients were included. At 52 weeks, 39.5% (34/76) of patients with disease activity at baseline were in CSFR. Out of the patients that met the criteria for DTT disease ( n = 68; 71%), 36.4% achieved CSFR. Treatment persistence at 52 weeks was 71.4% (CI 56.5–90.3) and 53.4% (CI 42.6–67.0) for non‐DTT and DTT patients, respectively. The main reasons for discontinuation of filgotinib were primary non‐response ( n = 21, 54%) or secondary loss of response ( n = 8, 23%). No severe infections were documented. Most reported adverse events included headache ( n = 5), nausea ( n = 3) and hypercholesterolemia ( n = 3).

Conclusion

Filgotinib is an effective and well‐tolerated treatment option for UC, including DTT disease. No new safety signals were found.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativePyridinesTriazolesHumansMaleFemaleAdultRegistriesMiddle AgedTreatment OutcomeNetherlandsProspective StudiesRemission InductionJanus Kinase 1AgedJanus Kinase InhibitorsSeverity of Illness IndexLeukocyte L1 Antigen ComplexYoung AdultC-Reactive Protein

Stichwörter der Autor:innen

difficult‐to‐treatfilgotinibreal‐worldulcerative colitis

Substanzen

GLPG0634PyridinesTriazolesJanus Kinase 1Janus Kinase InhibitorsLeukocyte L1 Antigen ComplexJAK1 protein, humanC-Reactive Protein

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Department of Gastroenterology and Hepatology, Zuyderland Hospital, Sittard, the Netherlands.
  • Amphia Hospital, Breda, the Netherlands.
  • Maastricht University Medical Centre, Maastricht, the Netherlands.

ORCID-Profile: M R Naber, P W Voorneveld, S H C Veltkamp, A A van Bodegraven, Z Mujagic, M Pierik, L M M Verleye, M Duijvestein, D G Bouwknegt, M C Visschedijk, F D M van Schaik

Förderung

  • Initiative on Crohn and Colitis

Zitieren

APA

Naber, M. R., van der Meulen, A. E., Voorneveld, P. W., Veltkamp, S. H. C., van Bodegraven, A. A., Bodelier, A., Mujagic, Z., Pierik, M., Verleye, L. M. M., Duijvestein, M., Bouwknegt, D. G., Visschedijk, M. C., Srivastava, N., West, R. L., Oldenburg, B., Löwenberg, M., van Schaik, F. D. M., & Dutch ICC Registry (2026). Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. United European Gastroenterology Journal, 14(1). https://doi.org/10.1002/ueg2.70141

Vancouver

Naber MR, van der Meulen AE, Voorneveld PW, Veltkamp SHC, van Bodegraven AA, Bodelier A, et al. Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry. United European Gastroenterology Journal. 2026;14(1). doi:10.1002/ueg2.70141

BibTeX
@article{Naber2026,
  author = {Naber, M R and van der Meulen, A E and Voorneveld, P W and Veltkamp, S H C and van Bodegraven, A A and Bodelier, A and Mujagic, Z and Pierik, M and Verleye, L M M and Duijvestein, M and Bouwknegt, D G and Visschedijk, M C and Srivastava, N and West, R L and Oldenburg, B and Löwenberg, M and van Schaik, F D M and Dutch ICC Registry, Dutch ICC Registry},
  title = {Filgotinib Is an Effective and Safe Treatment Option for Difficult‐To‐Treat Ulcerative Colitis: Real‐World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  volume = {14},
  number = {1},
  doi = {10.1002/ueg2.70141}
}
Kostenlos starten →